Agrylin

Thrombocythemia, Myeloproliferative Disorders (MPD)
Treatment
2 FDA approvals
5 Active Studies for Agrylin

What is Agrylin

AnagrelideThe Generic name of this drug
Treatment SummaryAnagrelide is a medication used to reduce high platelet levels in people with myeloproliferative neoplasms. It was approved in 1997 and has been found to be more effective and better tolerated than other platelet-reducing medications such as busulfan and hydroxyurea. Anagrelide comes in the form of an oral pill.
Agrylinis the brand name
image of different drug pills on a surface
Agrylin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Agrylin
Anagrelide
1997
14

Approved as Treatment by the FDA

Anagrelide, commonly known as Agrylin, is approved by the FDA for 2 uses like Thrombocythemia and Myeloproliferative Disorders (MPD) .
Thrombocythemia
Myeloproliferative Disorders (MPD)

Effectiveness

How Agrylin Affects PatientsAnagrelide reduces the number of platelets in the blood by blocking the production of the cells that create them. It needs to be taken several times a day, but it may take up to two weeks for it to start having an effect. Animal studies suggest it could affect female fertility, so women should be warned of this risk before taking the drug.
How Agrylin works in the bodyAnagrelide works to reduce platelet count, but it isn't clear exactly how. It seems to disrupt the development of megakaryocytes, the cells that produce platelets, which leads to a decrease in their size and number. Anagrelide is also known to block an enzyme called phosphodiesterase 3A, but this effect doesn't appear to be related to its impact on platelet counts. It is possible that this blocking action prevents cells from dividing and can lead to apoptosis, making it useful in the treatment of certain types of cancer.

When to interrupt dosage

The prescribed dosage of Agrylin is contingent upon the diagnosed condition. The quantity of dosage is contingent upon the mode of administration featured in the table below.
Condition
Dosage
Administration
Thrombocythemia
0.5 mg, , 1.0 mg
, Oral, Capsule, Capsule - Oral
Myeloproliferative Disorders (MPD)
0.5 mg, , 1.0 mg
, Oral, Capsule, Capsule - Oral

Warnings

Agrylin has a single contraindication, so it should not be employed in combination with the conditions listed in the table below.Agrylin Contraindications
Condition
Risk Level
Notes
Severe Hepatic Impairment
Do Not Combine
There are 20 known major drug interactions with Agrylin.
Common Agrylin Drug Interactions
Drug Name
Risk Level
Description
Abrocitinib
Major
The risk or severity of bleeding and thrombocytopenia can be increased when Anagrelide is combined with Abrocitinib.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Anagrelide.
Amiodarone
Major
The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Amiodarone.
Amrinone
Major
The risk or severity of congestive heart failure, bleeding, hypotension, and Tachycardia can be increased when Anagrelide is combined with Amrinone.
Arsenic trioxide
Major
The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Arsenic trioxide.
Agrylin Toxicity & Overdose RiskThe least toxic dose of anagrelide for rats is greater than 1500mg/kg and for mice is greater than 2500mg/kg. Overdoses may cause low blood pressure, rapid heartbeat, and vomiting. Since anagrelide reduces platelet counts, overdoses can lead to dangerously low platelet levels. Treatment for anagrelide overdoses should involve monitoring for bleeding or other related complications, as well as providing any necessary supportive measures.

Agrylin Novel Uses: Which Conditions Have a Clinical Trial Featuring Agrylin?

Currently, two clinical trials are underway to evaluate the potential of Agrylin in ameliorating Myeloproliferative Disorders (MPD).
Condition
Clinical Trials
Trial Phases
Myeloproliferative Disorders (MPD)
5 Actively Recruiting
Not Applicable, Phase 2, Phase 3, Phase 1
Thrombocythemia
0 Actively Recruiting

Agrylin Reviews: What are patients saying about Agrylin?

5Patient Review
11/19/2011
Agrylin for Elevated Platelets with Rapid Growth of Bone Marrow
I've been using Agrylin for eight years now, and it's really helped me. My platelet count was 1.5 million when I started, and it's since come down to 400,000. The only side effects I've experienced are rapid heartbeats and some hair loss, but they're not big deals compared to the alternative.
5Patient Review
3/20/2012
Agrylin for Elevated Platelets with Rapid Growth of Bone Marrow
I've been on agrylin for three years now, and it's helped me bring my platelet count down from 100,000 to 397,000.
4.3Patient Review
6/14/2010
Agrylin for Elevated Platelets with Rapid Growth of Bone Marrow
I've been taking Agrylin for twelve years now. While the side effects can be tough to deal with (rapid heartbeat, shortness of breath), they're manageable. I take propanolol as needed and up my dosage if necessary; however, I would caution against taking more than the recommended amount.
4.3Patient Review
4/11/2013
Agrylin for Elevated Platelets with Rapid Growth of Bone Marrow
I've been on this medication since 2006, though not constantly. My reading is currently at 600-750. I often have a rapid heartbeat and sometimes my liver or spleen will hurt, in addition to general feelings of malaise and confusion. My doctor told me that 5% of ET patients will develop leukemia, but I hope he's wrong. In any case, I read some reviews and saw that some people are still alive after 18 years, so that's encouraging.
4.3Patient Review
12/31/2015
Agrylin for Elevated Platelets with Rapid Growth of Bone Marrow
I've been having trouble getting my hands on the medication recently. My doctor can't seem to find a pharmacy that stocks it. I ran out over Thanksgiving 2015 and still haven't had any luck finding a provider. If anyone knows where I could order this drug, that would be great.
4Patient Review
5/14/2010
Agrylin for Elevated Platelets with Rapid Growth of Bone Marrow
When I was diagnosed with high platelets, my count was at 1.4 million. Three years later, it is still around 600,000+, which should be under 400,000. I have a rapid heart rate after each dose, lasting about 30 minutes. I take 3 - .5 mg/day doses. I am tired a lot of the time, but feel better than I did when my platelet count was at 1.4 million. Exercise several times a week has also helped me keep my platelet count between 600 to 650,000.
4Patient Review
3/25/2010
Agrylin for Elevated Platelets with Rapid Growth of Bone Marrow
I have been taking this drug for a decade or more, and recently started having issues with my heart rate spiking when I wasn't doing anything active. Just weakness, along with the rapid heartbeat.
3Patient Review
2/1/2011
Agrylin for Osteoporosis
This drug is great. It really helped me.
3Patient Review
2/1/2011
Agrylin for Osteoporosis
This drug is effective. I'm grateful for modern medicine.
3Patient Review
2/1/2011
Agrylin for Osteoporosis
This drug really helped me. I'm grateful for modern medicine.
3Patient Review
2/4/2011
Agrylin for Osteoporosis
This drug is effective. I appreciate its help.
3Patient Review
2/4/2011
Agrylin for Osteoporosis
This drug is great. It really helped me out.
3Patient Review
2/1/2011
Agrylin for Osteoporosis
This drug is really helpful. I'm grateful for modern medicine.
3Patient Review
2/1/2011
Agrylin for Osteoporosis
This drug is great. It really helped me.
3Patient Review
2/1/2011
Agrylin for Osteoporosis
This drug is effective. I'm grateful for modern medicine.
3Patient Review
2/4/2011
Agrylin for Osteoporosis
This drug is great. I'm grateful for modern medicine.
3Patient Review
2/1/2011
Agrylin for Osteoporosis
This drug really helped me. I'm grateful for modern medicine.

Patient Q&A Section about agrylin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is anagrelide a chemotherapy drug?

"Anagrelide is not typically considered a chemotherapy drug, but some hospitals may classified it as such because it inhibits cell development. The regulations for prescribing this drug are similar to those governing actual chemotherapy drugs."

Answered by AI

What drug class is Agrylin?

"Agrylin is a drug that prevents the formation of blood clots. It belongs to a class of drugs called antiplatelet agents, PDE-3 inhibitors, and phospholipase A2 inhibitors."

Answered by AI

What is Agrylin used for?

"Anagrelide decreases the number of platelets in the blood.

Anagrelide can help treat thrombocythemia by lowering the number of platelets in the blood. This is because it prevents the bone marrow from making too many of them. Platelets are a blood cell that helps the body to form blood clots."

Answered by AI

Is Agrylin a blood thinner?

"Aspirin, clopidogrel (Plavix), dipyridamole (Persantine), and ticlopidine (Ticlid) belong to the class of antiplatelets.

No, anagrelide is not a blood clotting prevention medication. There are two different drug classes for medications that prevent blood clots: 1) anticoagulants work against clotting factors and 2) antiplatelets lower the number of platelets in the body. Aspirin, clopidogrel, dipyridamole, and ticlopidine belong to the class of antiplatelets."

Answered by AI

Clinical Trials for Agrylin

Have you considered Agrylin clinical trials? We made a collection of clinical trials featuring Agrylin, we think they might fit your search criteria.